Theravance Finds a Good Match for its Phase III-Ready Nebulised COPD Therapy in Mylan
By Heather Cartwright
Pharma Deals Review: Vol 2015 Issue 2 (Table of Contents)
Published: 19 Feb-2015
DOI: 10.3833/pdr.v2015.i2.2092 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a deal worth upto US$265 M, Theravance Biopharma has secured Mylan as a partner for the development and commercialisation of TD-4208, its Phase III-ready long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease that was previously licensed to GlaxoSmithKline...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS